Viridian CFO reports major equity awards and RSU vesting

Viridian Therapeutics Chief Financial Officer Seth Harmon reported multiple equity compensation moves.

Accepted by SEC EDGAR 03/04/2026 - 07:15 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Viridian Therapeutics Chief Financial Officer Seth Harmon reported multiple equity compensation moves. On March 2, 2026 he received a stock option covering 102,850 shares and 20,550 restricted stock units, each at a stated price of $0.00 per share. On March 3, 2026, 6,267 RSUs converted into common stock and 2,091 shares of common stock were withheld at $29.32 per share to cover taxes, leaving him with 7,790 common shares held directly.

Insider Trade Summary

6,267 shares exercised/converted

Exercise 5 txns

Insider Harmon Seth

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	6,267	$0.00	$0.00
Exercise	Common Stock	6,267	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,091	$29.32	$61K
Grant/Award	Stock Option (Right to Buy)	102,850	$0.00	$0.00
Grant/Award	Restricted Stock Units	20,550	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 102,850 contracts (Direct); Restricted Stock Units — 39,351 contracts (Direct); Common Stock — 7,790 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 102,850 contracts (Direct); Restricted Stock Units, 25,068 to 39,351 contracts (Direct); Common Stock, 3,614 to 7,790 shares (Direct)

Footnotes (5)

F1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
F2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
F3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
F4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
F5. Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRDN CFO Seth Harmon report on this Form 4?

Seth Harmon reported equity awards and related share movements. He received a stock option for 102,850 shares, 20,550 restricted stock units, RSUs converting into 6,267 common shares, and 2,091 shares withheld to satisfy tax obligations.

How many Viridian Therapeutics stock options did the VRDN CFO receive?

He received a stock option covering 102,850 shares of Viridian Therapeutics common stock. The option vests in 48 equal monthly installments after March 2, 2026, subject to his continued service with the company through each monthly vesting date.

What restricted stock unit (RSU) grants did the VRDN CFO receive?

He was granted 20,550 restricted stock units on March 2, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in four equal annual installments, subject to his continued service with Viridian Therapeutics.

Did the VRDN CFO sell Viridian Therapeutics shares in the open market?

The filing reports no open‑market sales. Instead, 2,091 common shares were disposed of at $29.32 per share to pay taxes through share withholding, a method described as payment of tax liability by delivering securities.

How many Viridian Therapeutics common shares does the VRDN CFO hold after these transactions?

Following the reported transactions, he directly holds 7,790 shares of Viridian Therapeutics common stock. This figure reflects RSU conversion into 6,267 shares and the withholding of 2,091 shares to cover tax obligations associated with the equity awards.

How do the VRDN CFO’s RSUs vest over time?

The reported RSU grants vest over four years. For the March 2, 2026 grant, 25% of the RSUs vest on each yearly anniversary, contingent on his continued service with Viridian Therapeutics through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Seth

(Last)

(First)

(Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		M		6,267	A	⁽²⁾	9,881⁽⁵⁾	D
Common Stock	03/03/2026		F		2,091	D	$29.32	7,790⁽⁵⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$30.25	03/02/2026		A		102,850		⁽¹⁾	03/02/2036	Common Stock	102,850	$0.00	102,850	D
Restricted Stock Units	⁽²⁾	03/02/2026		A		20,550		⁽³⁾	⁽³⁾	Common Stock	20,550	$0.00	20,550	D
Restricted Stock Units	⁽²⁾	03/03/2026		M			6,267	⁽⁴⁾	⁽⁴⁾	Common Stock	6,267	$0.00	18,801	D

Explanation of Responses:

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

5. Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

	Jennifer Tousignant, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR